Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine
- PMID: 28289991
- DOI: 10.1007/s10554-017-1101-7
Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine
Abstract
The purpose of this study was to compare different semi-automated late gadolinium enhancement (LGE) quantification techniques using gadobutrol and gadopentetate dimeglumine contrast agents with regard to the diagnosis of fibrotic myocardium in patients with hypertrophic cardiomyopathy (HCM). Thirty patients with HCM underwent two cardiac MRI protocols with use of gadobutrol and gadopentetate dimeglumine. Contrast-to-noise ratio (CNR) between LGE area and remote myocardium (CNRremote), between LGE area and left ventricular blood pool (CNRpool), and signal-to-noise ratio (SNR) in LGE were compared. The presence and quantity of LGE were determined by visual assessment. With signal threshold versus reference mean (STRM) based thresholds of 2 SD, 5 SD, and 6 SD above the mean signal intensity (SI) of reference myocardium, the full-width at half-maximum (FWHM) technique was used. The volume and segments of the LGE area were compared between the two types of contrast agents. LGE was present in 26 of 30 (86.6%) patients in both protocols. The CNRremote of fibrotic myocardium in gadobutrol and gadopentetate dimeglumine agents was 26.82 ± 14.24 and 21.46 ± 10.59, respectively (P < 0.05). The CNRpool was significantly higher in gadobutrol (9.32 ± 7.64 vs. 6.39 ± 6.11, P < 0.05). The SNR was higher in gadobutrol (33.36 ± 14.35 vs. 27.53 ± 10.91, P < 0.05). The volume of scar size in MR images acquired with gadobutrol were significantly higher than those with gadopentetate dimeglumine (P < 0.05), and the STRM of 5 SD technique showed the greatest agreement with visual assessment (ICC = 0.99) in both examinations. There was no significant difference in fibrotic segments of the fibrotic myocardium in the LGE area (P < 0.05). This study proved that the Gadobutrol was an effective contrast agent for LGE imaging with superior delineation of fibrotic myocardium as compared to gadopentetate dimeglumine. The 5 SD technique yields the closest approximation of the extent of LGE identified by visual assessment.
Keywords: Cardiovascular magnetic resonance (CMR); Contrast agent; Gadobutrol; Gadopentetate dimeglumine; Hypertrophic cardiomyopathy (HCM); Late gadolinium enhancement (LGE).
Similar articles
-
Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging.J Magn Reson Imaging. 2014 May;39(5):1153-60. doi: 10.1002/jmri.24264. Epub 2013 Oct 22. J Magn Reson Imaging. 2014. PMID: 24151119 Clinical Trial.
-
Accuracy and reproducibility of semi-automated late gadolinium enhancement quantification techniques in patients with hypertrophic cardiomyopathy.J Cardiovasc Magn Reson. 2014 Oct 7;16(1):85. doi: 10.1186/s12968-014-0085-x. J Cardiovasc Magn Reson. 2014. PMID: 25315701 Free PMC article.
-
Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine.Invest Radiol. 2012 Mar;47(3):183-8. doi: 10.1097/RLI.0b013e318236e354. Invest Radiol. 2012. PMID: 22183078 Clinical Trial.
-
Quantitative Late Gadolinium Enhancement Cardiac Magnetic Resonance and Sudden Death in Hypertrophic Cardiomyopathy: A Meta-Analysis.JACC Cardiovasc Imaging. 2024 May;17(5):489-497. doi: 10.1016/j.jcmg.2023.07.005. Epub 2023 Aug 23. JACC Cardiovasc Imaging. 2024. PMID: 37632503
-
Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.JACC Cardiovasc Imaging. 2016 Dec;9(12):1392-1402. doi: 10.1016/j.jcmg.2016.02.031. Epub 2016 Jul 20. JACC Cardiovasc Imaging. 2016. PMID: 27450876 Review.
Cited by
-
Gadobutrol: A Review in Contrast-Enhanced MRI and MRA.Clin Drug Investig. 2018 Aug;38(8):773-784. doi: 10.1007/s40261-018-0674-9. Clin Drug Investig. 2018. PMID: 30006819 Free PMC article. Review.
-
Myocardial Fibrosis Quantification Methods by Cardiovascular Magnetic Resonance Imaging in Patients with Fabry Disease.J Clin Med. 2024 Aug 26;13(17):5047. doi: 10.3390/jcm13175047. J Clin Med. 2024. PMID: 39274260 Free PMC article.
-
Electrocardiography based prediction of hypertrophy pattern and fibrosis amount in hypertrophic cardiomyopathy: comparative study with cardiac magnetic resonance imaging.Int J Cardiovasc Imaging. 2018 Oct;34(10):1619-1628. doi: 10.1007/s10554-018-1365-6. Epub 2018 May 4. Int J Cardiovasc Imaging. 2018. PMID: 29728953
-
Cardiovascular imaging 2017 in the International Journal of Cardiovascular Imaging.Int J Cardiovasc Imaging. 2018 Jun;34(6):833-848. doi: 10.1007/s10554-018-1349-6. Int J Cardiovasc Imaging. 2018. PMID: 29651658 No abstract available.
-
Heterogeneity of longitudinal and circumferential contraction in relation to late gadolinium enhancement in hypertrophic cardiomyopathy patients with preserved left ventricular ejection fraction.Jpn J Radiol. 2018 Feb;36(2):103-112. doi: 10.1007/s11604-017-0700-5. Epub 2017 Nov 9. Jpn J Radiol. 2018. PMID: 29119456
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources